iiinova — where your digital self keeps evolving

Constantinos Zambirinis, MD, MRes, FSSO @czambir.bsky.social · 07/02/2026

🛑New in @cp-cancercell.bsky.social: 🔬Tumors leverage 𝗵𝘆𝗽𝗼𝘅𝗶𝗮 to "lock" infiltrating 𝗻𝗲𝘂𝘁𝗿𝗼𝗽𝗵𝗶𝗹𝘀 into a 𝙩𝙚𝙧𝙢𝙞𝙣𝙖𝙡𝙡𝙮 𝙖𝙜𝙚𝙙, 𝙲𝙲𝙻𝟹ʰⁱ 𝙨𝙩𝙖𝙩𝙚. 🦠This transition triggers an autocrine CCL3-CCR1 survival loop that sustains TANs, and fuels tumor progression 𝗮𝗰𝗿𝗼𝘀𝘀 𝗺𝘂𝗹𝘁𝗶𝗽𝗹𝗲 𝗰𝗮𝗻𝗰𝗲𝗿 𝘁𝘆𝗽𝗲𝘀. tinyurl.com/2v96busn

000

Reposted by Constantinos Zambirinis, MD, MRes, FSSO

American Association for Cancer Research (AACR) @theaacr.bsky.social · 29/01/2026

A study in Clinical Cancer Research reports an investigational blood panel that uses 4 biomarkers— ANPEP, PIGR, CA19-9, THBS2—to detect pancreatic cancer more accurately than the current standard test. buff.ly/wW2OR2d @aacrjournals.bsky.social

11110

Reposted by Constantinos Zambirinis, MD, MRes, FSSO

Eric Topol @erictopol.bsky.social · 31/07/2025

Metformin, the first line drug for Type 2 diabetes, has been used for 60 years without a clearcut mechanism of action. It turns out it's not just reducing glucose output from the liver. Metformin also works via the brain www.science.org/doi/10.1126/...

science.org

Low-dose metformin requires brain Rap1 for its antidiabetic action

Metformin lowers blood glucose by inhibiting Rap1 in ventromedial hypothalamic neurons that regulate glucose balance.

333096

Reposted by Constantinos Zambirinis, MD, MRes, FSSO

Judit Svensson Arvelund @juditarvelund.bsky.social · 05/05/2025

Interesting preprint on TCR-pMHC prediction and functional validation, with a great thread! 👇🏼 By the Shumacher Lab

041

Constantinos Zambirinis, MD, MRes, FSSO @czambir.bsky.social · 21/04/2025

Risk of Colorectal Cancer Associated With Frequency of Colorectal Polyp Diagnosis in Relatives - @gastroenterology.bsky.social www.gastrojournal.org/article/S001...

010

Reposted by Constantinos Zambirinis, MD, MRes, FSSO

Nature @nature.com · 18/04/2025

The US National Institutes of Health has terminated nearly 800 research projects at a breakneck pace, wiping out significant chunks of funding to entire scientific fields Read the full story: go.nature.com/3EuFRPV

A graphic showing that 50.6% of research projects with "LGBT" search terms have been cancelled. 45.8% of grants with "transgender" in the search terms have been cancelled. 45.5% of research grants with "vaccine hesitancy" have been cancelled. 3.4% grants with "HIV" or "AIDS" have been cancelled.

5285217

Reposted by Constantinos Zambirinis, MD, MRes, FSSO

NEJM.org @nejm.org · 30/03/2025

For patients with IgG4-related disease, there are no approved therapies. Research findings on the efficacy and safety of inebilizumab ― a monoclonal antibody that targets and depletes CD19+ B-cells ― are summarized in a new Quick Take video. nej.md/421enZX #MedSky #RheumSky

nej.md

Inebilizumab for IgG4-Related Disease | NEJM

Quick Take Video Summary from The New England Journal of Medicine — Inebilizumab for IgG4-Related Disease

0285

Reposted by Constantinos Zambirinis, MD, MRes, FSSO

Institut Necker Enfants Malades @inem-necker.bsky.social · 26/03/2025

🚨 New: Spleen-resident macrophages (MMMs) can directly activate CD8+ T cells to fight tumors – independently of dendritic cells. They use a vacuolar MHC-I pathway & need Batf3 for this antitumor response. 🧠 A game-changer for immunotherapy? 🔗 www.cell.com/immunity/abs... @cp-immunity.bsky.social

065

Constantinos Zambirinis, MD, MRes, FSSO @czambir.bsky.social · 26/03/2025

Terrible indeed! Everyone should be supporting and advocating for MORE (not less) funding for research on such devastating diseases as Pancreatic Cancer, especially when their incidence is rising!... @pancan.bsky.social @pancreaticcanuk.bsky.social @pce-europe.bsky.social @letswinpc.bsky.social

021

Constantinos Zambirinis, MD, MRes, FSSO @czambir.bsky.social · 23/03/2025

Couldn't agree more with this. Precision dosing is the way. Max tolerated dose treatment by default, can detrimental for some patients, especially those that rely to a bigger extent on immune-mediated tumor control, and whose immune system is crippled by MTD chemo.

020

Constantinos Zambirinis, MD, MRes, FSSO @czambir.bsky.social · 20/03/2025

Kicking off an exciting Clinical Cancer Genomics 2025 conference with an overview of national molecular profiling strategies of 6 EU countries. Important points: -WGS provides prognostic info (not just actionable targets)! -Need to more data on various ancestries -Need to increase testing! #CCG2025

101

Reposted by Constantinos Zambirinis, MD, MRes, FSSO

NEJM.org @nejm.org · 18/03/2025

Learn more about the APAChE study: 📄 Read the full results published in NEJM: nej.md/3IrM6T8 📄 Read the editorial by Philip J. Landrigan, MD: nej.md/48CvGSs 📺 Watch the interview with Dr. Landrigan: nej.md/41SCs6f

054

Constantinos Zambirinis, MD, MRes, FSSO @czambir.bsky.social · 15/03/2025

Nice summary video by @nejm.org on the INSEMA trial 👉In T1/small T2 breast cancers with clinically negative axilla, omitting SLN Biopsy is non-inferior to performing it: ✅ est. 5y inv.DFS of 92% at 6 years median f/up ✅ signif. less lymphedema & arm pain/restriction www.nejm.org/do/10.1056/N...

nejm.org

Omitting Sentinel-Node Biopsy in Small Breast Cancers | NEJM

Quick Take Video Summary from The New England Journal of Medicine — Omitting Sentinel-Node Biopsy in Small Breast Cancers

100

Constantinos Zambirinis, MD, MRes, FSSO @czambir.bsky.social · 01/03/2025

This is consistent with our 2021 @annsurgoncology.bsky.social paper on resectable PDAC showing better OS after metachronous Extrahepatic-only recurrence, vs Liver recur: link.springer.com/article/10.1... 👉 PDAC #organotropism informs on tumor biologic aggressiveness. @metastasisresearch.bsky.social

100

Reposted by Constantinos Zambirinis, MD, MRes, FSSO

Nature Reviews Cancer @natrevcancer.nature.com · 12/02/2025

Miriam Merad & Co ‪@sinaiimmuno.bsky.social‬ outline the molecular basis of #DendriticCell maturation and the mechanisms through which cancer impairs #DC maturation and consider the potential for DC-focused cancer #immunotherapeutics. 📖 ⬇️

bit.ly

#REVIEW 🚨

063

Reposted by Constantinos Zambirinis, MD, MRes, FSSO

Pancreatic Cancer Action Network @pancan.bsky.social · 01/02/2025

In case you missed our live event covering the latest in #pancreaticcancer clinical trials, you can watch the full recording now at pancan.org/clinicaltrials2025 🔬💜 Learn from experts about the basics of clinical trials, what developments are on the horizon and how to find the right trial for you.

pancan.org

Clinical Trials: At the Leading Edge of Progress

Join PanCAN on Jan. 30, at 11 a.m. PT / 2 p.m. ET, for an educational discussion about pancreatic cancer clinical trials and new developments in the field. RSVP for the event here:…

073

Constantinos Zambirinis, MD, MRes, FSSO @czambir.bsky.social · 29/01/2025

Ok let's see what this platform has to offer, given X's decline... :)

010